Literature DB >> 8760716

Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.

S Tingulstad1, B Hagen, F E Skjeldestad, M Onsrud, T Kiserud, T Halvorsen, K Nustad.   

Abstract

OBJECTIVE: To evaluate the ability of a risk of malignancy index (RMI), based on a serum CA125 level, ultrasound findings and menopausal status, to discriminate a benign from a malignant pelvic mass and to discriminate early stage (Figo Stage I) from Stages II, III and IV of ovarian cancer.
DESIGN: A prospective study.
SETTING: Department of Gynaecology, Trondheim University Hospital, Trondheim, Norway. PARTICIPANTS: One hundred and seventy-three women, 30 years or older, consecutively admitted between February 1992 and February 1994 for primary laparotomy of a pelvic mass. MAIN OUTCOME MEASURES: The sensitivity, specificity and positive predictive value of serum CA125 level, ultrasound findings and menopausal status, separately and combined into the RMI, to diagnose ovarian cancer.
RESULTS: The RMI was more accurate than any individual criterion in diagnosing cancer. Using a RMI cut-off level of 200 to indicate malignancy, the RMI derived from this dataset gave a sensitivity of 80%, specificity of 92% and positive predictive value of 83%. Applying RMI criteria developed by others, the following test performance was found: sensitivity 71%, specificity 96% and positive predictive value 89%. For the Stages II, III and IV of ovarian cancer the sensitivity increased to approximately 90% without any substantial loss in specificity.
CONCLUSIONS: The risk of malignancy index is able to correctly discriminate between malignant and benign pelvic masses. It is a scoring system which can be introduced easily into clinical practice to facilitate the selection of patients for primary surgery at an oncological unit.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760716     DOI: 10.1111/j.1471-0528.1996.tb09882.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  51 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

2.  Performance of laparoscopy in identifying malignant ovarian cysts.

Authors:  C Bensaid; M A Le Frère Belda; U Metzger; F Larousserie; D Clément; G Chatellier; F Lécuru
Journal:  Surg Endosc       Date:  2006-06-26       Impact factor: 4.584

Review 3.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

4.  Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.

Authors:  Khawla Al Musalhi; Manal Al Kindi; Faiza Al Aisary; Fatma Ramadhan; Thuraya Al Rawahi; Khalsa Al Hatali; Waad-Allah Mula-Abed
Journal:  Oman Med J       Date:  2016-09

5.  Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  A Oaknin; R Guarch; P Barretina; D Hardisson; A González-Martín; X Matías-Guiu; A Pérez-Fidalgo; B Vieites; I Romero; J Palacios
Journal:  Clin Transl Oncol       Date:  2017-08-16       Impact factor: 3.405

6.  The role of CA125 in clinical practice.

Authors:  E L Moss; J Hollingworth; T M Reynolds
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

7.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

8.  Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Expert Opin Med Diagn       Date:  2012-03

9.  Risk of malignancy index as an evaluation of preoperative pelvic mass.

Authors:  Zinatossadat Bouzari; Shahla Yazdani; Ziba Shirkhani Kelagar; Narges Abbaszadeh
Journal:  Caspian J Intern Med       Date:  2011

Review 10.  Current state of biomarker development for clinical application in epithelial ovarian cancer.

Authors:  Richard G Moore; Shannon MacLaughlan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2009-10-31       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.